Exploring the Neuroprotective Role of Selenium: Implications and Perspectives for Central Nervous System Disorders

Abstract

Selenium (Se) is a crucial element in selenoproteins, key biomolecules for physiological function in vivo. As a selenium-rich organ, the central nervous system can express all 25 kinds of selenoproteins, which protect neurons by reducing oxidative stress and inflammatory response. However, decreased Se levels are prevalent in a variety of neurological disorders, which is not conducive to the treatment and prognosis of patients. Thus, the biological study of Se has emerged as a focal point in investigating the pivotal role of trace elements in neuroprotection. This paper presents a comprehensive review of the pathogenic mechanism of neurological diseases, the protective mechanism of Se, and the neurological protective function of selenoproteins. Additionally, the application of Se as a neuroprotective agent in neurological disorder therapy, including ischemic stroke, Alzheimer's, Parkinson's, and other neurological diseases, is summarized. The present review aims to offer novel insights and methodologies for the prevention and treatment of neurological disorders with trace Se, providing a scientific basis for the development of innovative Se-based neuroprotectants to promote their clinical application against neurological diseases.

Keywords

nervous system disorders / neuroprotection / selenium / selenoproteins

References

[1] A. E. Carlisle, N. Lee, A. N. Matthew-Onabanjo, et al., “Selenium Detoxification is Required for Cancer-Cell Survival,” Nature Metabolism 2 (2020): 603.

[2] A. Thaenert, A. Sevostyanova, C. Z. Chung, O. Vargas-Rodriguez, S. V. Melnikov, and D. Soll, “Engineered mRNA-Ribosome Fusions for Facile Biosynthesis of Selenoproteins,” Proceedings National Academy of Science USA 121 (2024): e2321700121.

[3] C. Vindry, O. Guillin, P. Wolff, et al., “A Homozygous Mutation in the Human Selenocysteine tRNA Gene Impairs UGA Recoding Activity and Selenoproteome Regulation by Selenium,” Nucleic Acids Research 51 (2023): 7580-7601.

[4] T. Hilal, B. Y. Killam, M. Grozdanovic, et al., “Structure of the Mammalian Ribosome as it Decodes the Selenocysteine UGA Codon,” Science 376 (2022): 1338-1343.

[5] B. K. Shimada, N. Alfulaij, and L. A. Seale, “The Impact of Selenium Deficiency on Cardiovascular Function,” International Journal of Molecular Sciences 22 (2021): 10713.

[6] WHO Expert Committee, “Trace Elements in Human Nutrition. Report of a WHO Expert Committee,” World Health Organization Technical Report Series 532, (1973): 1-65.

[7] Z. Qi, A. Duan, and K. Ng, “Selenosugar, Selenopolysaccharide, and Putative Selenoflavonoid in Plants,” Comprehensive Reviews in Food Science and Food Safety 23 (2024): e13329.

[8] Z. Miao, W. Wang, Z. Miao, Q. Cao, and S. Xu, “Role of Selenoprotein W in Participating in the Progression of Non-Alcoholic Fatty Liver Disease,” Redox Biology 71 (2024): 103114.

[9] P. Ouyang, Z. Cai, J. Peng, et al., “SELENOK-Dependent CD36 Palmitoylation Regulates Microglial Functions and Aβ Phagocytosis,” Redox Biology 70 (2024): 103064.

[10] E. A. Turovsky, A. S. Baryshev, and E. Y. Plotnikov, “Selenium Nanoparticles in Protecting the Brain From Stroke: Possible Signaling and Metabolic Mechanisms,” Nanomaterials 14 (2024): 160.

[11] B. Chen, Y. Hong, X. Zhai, et al., “m6A and m5C Modification of GPX4 Facilitates Anticancer Immunity via STING Activation,” Cell Death and Disease 14 (2023): 809.

[12] R. Brigelius-Flohe, “Tissue-Specific Functions of individual Glutathione Peroxidases,” Free Radical Biology and Medicine 27 (1999): 951-965.

[13] R. Tian, A. Abarientos, J. Hong, et al., “Genome-Wide CRISPRi/A Screens In Human Neurons Link Lysosomal Failure to Ferroptosis,” Nature Neuroscience 24 (2021): 1020-1034.

[14] M. P. Rayman and M. P. Rayman, “The Argument for Increasing Selenium Intake,” Proceedings of the Nutrition Society 61 (2002): 203-215.

[15] H. Wu, G. Zhao, S. Liu, et al., “Supplementation With Selenium Attenuates Autism-Like Behaviors and Improves Oxidative Stress, Inflammation and Related Gene Expression in an Autism Disease Model,” Journal of Nutritional Biochemistry 107 (2022): 109034.

[16] K. D. Zhu, S. H. Yang, T. Li, et al., “Advances in the Study of the Mechanism by Which Selenium and Selenoproteins Boost Immunity to Prevent Food Allergies,” Nutrients 14 (2022): 3133.

[17] D. Behne and A. Kyriakopoulos, “Mammalian Selenium -Containing Proteins,” Annual Review of Nutrition 21 (2001): 453-473.

[18] A. Joorabloo and T. Liu, “Recent Advances in Reactive Oxygen Species Scavenging Nanomaterials for Wound Healing,” Exploration 4 (2024): 20230066.

[19] T. Wirth, “Small Organoselenium Compounds: More than just Glutathione Peroxidase Mimics,” Angewandte Chemie International Edition 54 (2015): 10074-10076.

[20] F. P. Bellinger, M. T. Bellinger, L. A. Seale, et al., “Glutathione Peroxidase 4 is associated with Neuromelanin in Substantia Nigra and Dystrophic Axons in Putamen of Parkinson's Brain,” Molecular Neurodegeneration 6 (2011): 8.

[21] W. Y. Shi, S. B. Sun, H. W. Liu, et al., “ROS Systems are a New Integrated Network for Sensing Homeostasis and Alarming Stresses in Organelle Metabolic Processes,” Redox Biology 70 (2024): 103050.

[22] H. Pothion, C. Jehan, H. Tostivint, et al., “Selenoprotein T: An Essential Oxidoreductase Serving as a Guardian of Endoplasmic Reticulum Homeostasis,” Antioxidants and Redox Signaling 33 (2020): 1257-1275.

[23] G. Talibova, Z. Ozturk, M. Parlak, and A. Kupesiz, “Elevated Selenoprotein P Levels in Thalassemia Major Patients,” Archives of Medical Research 53 (2022): 508-515.

[24] A. A. Turanov, V. A. Shchedrina, R. A. Everley, et al., “Selenoprotein S is Involved in Maintenance and Transport of Multiprotein Complexes,” Biochemical Journal 462 (2014): 555-565.

[25] C. C. Sun, Z. R. Du, X. Liu, et al., “Selenium Forms and Dosages Determined Their Biological Actions in Mouse Models of Parkinson's Disease,” Nutrients 15 (2023): 11.

[26] U. Schweizer and M. Fabiano, “Selenoproteins in Brain Development and Function,” Free Radical Biology and Medicine 190 (2022): 105-115.

[27] H. Wang, W. Ma, W. Hu, et al., “Cathodal Bilateral transcranial Direct-Current Stimulation Regulates Selenium to Confer Neuroprotection After Rat Cerebral Ischaemia-Reperfusion Injury,” Journal of Physiology 602 (2024): 1175-1197.

[28] J. Yang, R. Zhang, H. Zhao, et al., “Bioinspired Copper Single-Atom Nanozyme as a Superoxide Dismutase-Like Antioxidant for Sepsis Treatment,” Exploration 2 (2022): 20210267.

[29] N. Boonpraman and S. S. Yi, “NADPH Oxidase 4 (NOX4) as a Biomarker and Therapeutic Target in Neurodegenerative Diseases,” Neural Regeneration Research 19 (2024): 1961-1966.

[30] Y. Li, J. Liao, L. Xiong, et al., “Stepwise Targeted Strategies for Improving Neurological Function by Inhibiting Oxidative Stress Levels and Inflammation Following Ischemic Stroke,” Journal of Controlled Release 368 (2024): 607-622.

[31] M. Scholefield, S. Patassini, J. Xu, and G. J. S. Cooper, “Widespread Selenium Deficiency in the Brain of Cases With Huntington's Disease Presents a New Potential Therapeutic Target,” EBioMedicine 97 (2023): 104824.

[32] X. Liang, Z. Xue, Y. Zheng, et al., “Selenium Supplementation Enhanced the Expression of Selenoproteins in Hippocampus and Played a Neuroprotective Role in LPS-Induced Neuroinflammation,” International Journal of Biological Macromolecules 234 (2023): 123740.

[33] N. Sharma, E. J. Shin, D. T. Pham, et al., “GPx-1-Encoded Adenoviral Vector Attenuates Dopaminergic Impairments Induced by Methamphetamine in GPx-1 Knockout Mice Through Modulation of NF-κB Transcription Factor,” Food and Chemical Toxicology 154 (2021): 112313.

[34] E. J. Shin, Y. H. Chung, N. Sharma, et al., “Glutathione Peroxidase-1 Knockout Facilitates Memory Impairment Induced by β-Amyloid (1-42) in Mice via Inhibition of PKC βII-Mediated ERK Signaling; Application With Glutathione Peroxidase-1 Gene-Encoded Adenovirus Vector,” Neurochemical Research 45 (2020): 2991-3002.

[35] X. Chen, G. Fu, L. Li, Q. Zhao, Z. Ke, and R. Zhang, “Selenoprotein GPX1 is a Prognostic and Chemotherapy-Related Biomarker for Brain Lower Grade Glioma,” Journal of Trace Elements in Medicine and Biology 74 (2022): 127082.

[36] W. Zhang, Y. Liu, Y. Liao, C. Zhu, and Z. Zou, “GPX4, Ferroptosis, and Diseases,” Biomedicine and Pharmacotherapy 174 (2024): 116512.

[37] J. Jia, G. Xu, D. Zhu, H. Liu, X. Zeng, and L. Li, “Advances in the Functions of Thioredoxin System in Central Nervous System Diseases,” Antioxidats and Redox Signaling 38 (2023): 425-441.

[38] G. Bjorklund, L. Zou, M. Peana, et al., “The Role of the Thioredoxin System in Brain Diseases,” Antioxidants 11 (2022): 2161.

[39] S. Peng, Y. Chen, R. Wang, and J. Zhang, “Z-Ligustilide Provides a Neuroprotective Effect by Regulating the Phenotypic Polarization of Microglia via Activating Nrf2-TrxR Axis in the Parkinson's Disease Mouse Model,” Redox Biology 76 (2024): 103324.

[40] S. Kurokawa, K. E. Hill, W. H. McDonald, and R. F. Burk, “Long Isoform Mouse Selenoprotein P (Sepp1) Supplies Rat Myoblast L8 Cells With Selenium via Endocytosis Mediated by Heparin Binding Properties and Apolipoprotein E Receptor-2 (ApoER2),” Journal of Biological Chemistry 287 (2012): 28717-28726.

[41] F. P. Bellinger, A. V. Raman, R. H. Rueli, et al., “Changes in Selenoprotein P in Substantia Nigra and Putamen in Parkinson's Disease,” Journal of Parkinson's Disease 2 (2012): 115-126.

[42] J. Bang, D. Kang, J. Jung, et al., “SEPHS1: Its Evolution, Function and Roles in Development and Diseases,” Archives of Biochemistry and Biophysics 730 (2022): 109426.

[43] H. Xia, Y. Wang, J. Dai, et al., “Selenoprotein K is Essential for the Migration and Phagocytosis of Immature Dendritic Cells,” Antioxidants 11 (2022): 1264.

[44] X. L. Meng, C. L. Chen, Y. Y. Liu, et al., “Selenoprotein SELENOK Enhances the Migration and Phagocytosis of Microglial Cells by Increasing the Cytosolic Free Ca2+ Level Resulted From the Up-Regulation of IP3R,” Neuroscience 406 (2019): 38-49.

[45] D. Y. Hwang, J. S. Sin, M. S. Kim, et al., “Overexpression of Human Selenoprotein M Differentially Regulated the Concentrations of Antioxidants and H₂O₂, the Activity of Antioxidant Enzymes, and the Composition of White Blood Cells in a Transgenic Rat,” International Journal of Molecular Medicine 21 (2008): 169-179.

[46] S. Y. Yim, K. R. Chae, S. B. Shim, et al., “ERK Activation Induced by Selenium Treatment Significantly Downregulates β/γ-Secretase Activity and Tau Phosphorylation in the Transgenic Rat Overexpressing Human Selenoprotein M,” International Journal of Molecular Medicine 24 (2009): 91-96.

[47] M. A. Reeves, F. P. Bellinger, and M. J. Berry, “The Neuroprotective Functions of Selenoprotein M and Its Role in Cytosolic Calcium Regulation,” Antioxidants and Redox Signaling 12 (2010): 809-818.

[48] H. Y. Kim and V. N. Gladyshev, “Methionine Sulfoxide Reductases: Selenoprotein Forms and Roles in Antioxidant Protein Repair in Mammals,” Biochemical Journal 407 (2007): 321-329.

[49] S. Salaramoli, H. R. Joshaghani, M. Hosseini, and S. I. Hashemy, “Therapeutic Effects of Selenium on Alpha-Synuclein Accumulation in Substantia Nigra Pars Compacta in a Rat Model of Parkinson's Disease: Behavioral and Biochemical Outcomes,” Biological Trace Element Research 202 (2024): 1115-1125.

[50] R. H. Rueli, D. J. Torres, A. S. Dewing, et al., “Selenoprotein S Reduces Endoplasmic Reticulum Stress-Induced Phosphorylation of Tau: Potential Role in Selenate Mitigation of Tau Pathology,” Journal of Alzheimer's Disease 55 (2017): 749-762.

[51] N. Fradejas, C. Serrano-Perez Mdel, P. Tranque, and S. Calvo, “Selenoprotein S Expression in Reactive Astrocytes Following Brain Injury,” Glia 59 (2011): 959-972.

[52] E. G. Varlamova, M. V. Goltyaev, and E. A. Turovsky, “The Role of Selenoproteins SELENOM and SELENOT in the Regulation of Apoptosis, ER Stress, and Calcium Homeostasis in the A-172 Human Glioblastoma Cell Line,” Biology 11 (2022): 811.

[53] A. V. Raman, M. W. Pitts, A. Seyedali, A. C. Hashimoto, F. P. Bellinger, and M. J. Berry, “Selenoprotein W Expression and Regulation in Mouse Brain and Neurons,” Brain and Behavior 3 (2013): 562-574.

[54] J. Xu, X. Wang, H. Yin, et al., “Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke,” ACS Nano 13 (2019): 8577-8588.

[55] T. Tao, M. Liu, M. Chen, et al., “Natural Medicine in Neuroprotection for Ischemic Stroke: Challenges and Prospective,” Pharmacology and Therapeutics 216 (2020): 107695.

[56] Y. Zhang, H. Liu, and J. Ding, “Brain-Targeted Drug Delivery Platforms for Ischemic Stroke Therapy,” BME Frontiers 5 (2024): 0055.

[57] S. Blanco, E. Martinez-Lara, E. Siles, and M. A. Peinado, “New Strategies for Stroke Therapy: Nanoencapsulated Neuroglobin,” Pharmaceutics 14 (2022): 1737.

[58] Y. Du, Y. Huo, Q. Yang, et al., “Ultrasmall Iron-Gallic Acid Coordination Polymer Nanodots with Antioxidative Neuroprotection for PET/MR Imaging-Guided Ischemia Stroke Therapy,” Exploration 3 (2023): 20220041.

[59] G. A. Donnan and S. M. Davis, “Breaking the 3 h Barrier for Treatment of Acute Ischaemic Stroke,” Lancet Neurology 7 (2008): 981-982.

[60] J. Hu, S. Huang, L. Zhu, et al., “Tissue Plasminogen Activator-Porous Magnetic Microrods for Targeted Thrombolytic Therapy After Ischemic Stroke,” ACS Applied Materials Interfaces 10 (2018): 32988-32997.

[61] M. I. Ayuso and J. Montaner, “Advanced Neuroprotection for Brain Ischemia: An Alternative Approach to Minimize Stroke Damage,” Expert Opinion on Investigational Drugs 24 (2015): 1137-1142.

[62] X. R. Lee and G. L. Xiang, “Effects of Edaravone, the Free Radical Scavenger, on Outcomes in Acute Cerebral Infarction Patients Treated With Ultra-Early Thrombolysis of Recombinant Tissue Plasminogen Activator,” Clinical Neurology and Neurosurgery 167 (2018): 157-161.

[63] Y. Zhao, Z. Zhang, Z. Pan, and Y. Liu, “Advanced Bioactive Nanomaterials for Biomedical Applications,” Exploration 1 (2021): 20210089.

[64] J. Yang, L. Wang, L. Huang, et al., “Receptor-Targeting Nanomaterials Alleviate Binge Drinking-Induced Neurodegeneration as Artificial Neurotrophins,” Exploration 1 (2021): 61-74.

[65] Z. Cao, J. Liu, and X. Yang, “Deformable Nanocarriers for Enhanced Drug Delivery and Cancer Therapy,” Exploration 4 (2024): 20230037.

[66] Y. Zhang, Z. Zou, S. Liu, et al., “Edaravone-Loaded Poly(Amino Acid) Nanogel Inhibits Ferroptosis for Neuroprotection in Cerebral Ischemia Injury,” Asian Journal of Pharmaceutical Sciences 19 (2024): 100886.

[67] A. Dominiak, A. Wilkaniec, P. Wroczynski, and A. Adamczyk, “Selenium in the Therapy of Neurological Diseases. Where Is It Going?,” Current Neuropharmacology 14 (2016): 282-299.

[68] J. Tehse and C. Taghibiglou, “The Overlooked Aspect of Excitotoxicity: Glutamate-Independent Excitotoxicity in Traumatic Brain Injuries,” European Journal of Neuroscience 49 (2019): 1157-1170.

[69] R. M. Adibhatla and J. F. Hatcher, “Phospholipase A2, Reactive Oxygen Species, and Lipid Peroxidation in Cerebral Ischemia,” Free Radical Biology and Medicine 40 (2006): 376-387.

[70] L. Li, Y. Shen, Z. Tang, et al., “Engineered Nanodrug Targeting Oxidative Stress for Treatment of Acute Kidney Injury,” Exploration 3 (2023): 2022 0148.

[71] Z. Zhuo, H. M. Wang, S. Zhang, P. F. Bartlett, T. L. Walker, and S. T. Hou, “Selenium Supplementation Provides Potent Neuroprotection Following Cerebral Ischemia in Mice,” Journal of Cerebral Blood Flow and Metabolism 43 (2023): 1060-1076.

[72] M. Alanne, K. Kristiansson, K. Auro, et al., “Variation in the Selenoprotein S Gene Locus Is Associated with Coronary Heart Disease and Ischemic Stroke in Two Independent Finnish Cohorts,” Human Genetics 122 (2007): 355-365.

[73] D. E. Handy and J. Loscalzo, “The Role of Glutathione Peroxidase-1 in Health and Disease,” Free Radical Biology and Medicine 188 (2022): 146-161.

[74] B. K. Sarma and G. Mugesh, “Glutathione Peroxidase (GPx)-Like Antioxidant Activity of the Organoselenium Drug Ebselen:  Unexpected Complications with Thiol Exchange Reactions,” Journal of the American Chemical Society 127 (2005): 11477-11485.

[75] F. F. Ramli, N. Singh, U. E. Emir, et al., “Effects of Ebselen Addition on Emotional Processing and Brain Neurochemistry in Depressed Patients Unresponsive to Antidepressant Medication,” Translational Psychiatry 14 (2024): 200.

[76] J. Kil, E. Lobarinas, C. Spankovich, et al., “Safety and Efficacy of Ebselen for the Prevention of Noise-Induced Hearing Loss: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial,” Lancet 390 (2017): 969-979.

[77] N. Ishibashi, O. Prokopenko, M. Weisbrot-Lefkowitza, K. R. Reuhl, and O. Mirochnitchenko, “Glutathione Peroxidase Inhibits Cell Death and Glial Activation Following Experimental Stroke,” Molecular Brain Research 109 (2002): 34-44.

[78] I. Ingold, C. Berndt, S. Schmitt, et al., “Selenium Utilization by GPX4 is Required to Prevent Hydroperoxide-Induced Ferroptosis,” Cell 172 (2018): 409-422.e21.

[79] B. Lu, X. B. Chen, M. D. Ying, Q. J. He, J. Cao, and B. Yang, “The Role of Ferroptosis in Cancer Development and Treatment Response,” Frontiers in Pharmacology 8 (2017): 992.

[80] Q. Li, X. Han, X. Lan, et al., “Inhibition of Neuronal Ferroptosis Protects Hemorrhagic Brain,” JCI Insight 2 (2017): e90777.

[81] X. N. Li, L. Lin, X. W. Li, et al., “BSA-Stabilized Selenium Nanoparticles Ameliorate Intracerebral Hemorrhage's-Like Pathology by Inhibiting Ferroptosis-Mediated Neurotoxicology via Nrf2/GPX4 Axis Activation,” Redox Biology 75 (2024): 103268.

[82] A. Tarangelo, L. Magtanong, K. T. Bieging-Rolett, et al., “p53 Suppresses Metabolic Stress-Induced Ferroptosis in Cancer Cells,” Cell Reports 22 (2018): 569-575.

[83] R. E. Haskew-Layton, J. B. Payappilly, N. A. Smirnova, et al., “Controlled Enzymatic Production of Astrocytic Hydrogen Peroxide Protects Neurons from Oxidative Stress via an Nrf2-Independent Pathway,” Proceedings National Academy of Science USA 107 (2010): 17385-17390.

[84] Z. Fan, A. K. Wirth, D. Chen, et al., “Nrf2-Keap1 Pathway Promotes Cell Proliferation and Diminishes Ferroptosis,” Oncogenesis 6 (2017): e371.

[85] I. Alim, J. T. Caulfield, Y. Chen, et al., “Selenium Drives a Transcriptional Adaptive Program to Block Ferroptosis and Treat Stroke,” Cell 177 (2019): 1262-1279.e25.

[86] S. Shukla and B. L. Tekwani, “Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation,” Frontiers in Pharmacology 11 (2020): 537.

[87] W. C. Shi, X. B. Wei, Z. Y. Wang, et al., “HDAC 9 Exacerbates Endothelial Injury in Cerebral Ischaemia/Reperfusion Injury,” Journal of Cellular and Molecular Medicine 20 (2016): 1139-1149.

[88] S. Lu, H. Li, K. Li, and X. D. Fan, “HDAC9 Promotes Brain Ischemic Injury by Provoking IκBα/NF-κB and MAPKs Signaling Pathways,” Biochemical and Biophysical Research Communications 503 (2018): 1322-1329.

[89] L. J. Zhong, J. X. Yan, H. T. Li, and L. Meng, “HDAC9 Silencing Exerts Neuroprotection Against Ischemic Brain Injury via miR-20a-Dependent Downregulation of NeuroD1,” Frontiers in Cellular Neuroscience 14 (2021): 544285.

[90] L. Sanguigno, N. Guida, S. Anzilotti, et al., “Stroke by Inducing HDAC9-Dependent Deacetylation of HIF-1 and Sp1, Promotes TfR1 Transcription and GPX4 Reduction, Thus Determining Ferroptotic Neuronal Death,” International Journal of Biological Sciences 19 (2023): 2695-2710.

[91] B. Hoehn, M. A. Yenari, R. M. Sapolsky, and G. K. Steinberg, “Glutathione Peroxidase Overexpression Inhibits Cytochrome c Release and Proapoptotic Mediators to Protect Neurons from Experimental Stroke,” Stroke; A Journal of Cerebral Circulation 34 (2003): 2489-2494.

[92] P. Scheltens, K. Blennow, M. M. B. Breteler, et al., “Alzheimer's Disease,” Lancet 388 (2016): 505-517.

[93] H. Hampel, J. Hardy, K. Blennow, et al., “The Amyloid-β Pathway in Alzheimer's Disease,” Molecular Psychiatry 26 (2021): 5481-5503.

[94] D. J. Selkoe and J. Hardy, “The Amyloid Hypothesis of Alzheimer's Disease at 25 Years,” EMBO Molecular Medicine 8 (2016): 595-608.

[95] Y. J. Chen and Y. Yu, “Tau and Neuroinflammation in Alzheimer's Disease: Interplay Mechanisms and Clinical Translation,” Journal of Neuroinflammation 20 (2023): 165.

[96] N. J. Janocko, K. A. Brodersen, A. I. Soto-Ortolaza, et al., “Neuropathologically Defined Subtypes of Alzheimer's Disease Differ Significantly From Neurofibrillary Tangle-Predominant Dementia,” Acta Neuropathologica 124 (2012): 681-692.

[97] J. M. Long and D. M. Holtzman, “Alzheimer Disease: An Update on Pathobiology and Treatment Strategies,” Cell 179 (2019): 312-339.

[98] M. M. Wen, N. S. El-Salamouni, W. M. El-Refaie, et al., “Nanotechnology-Based Drug Delivery Systems for Alzheimer's Disease Management: Technical, Industrial, and Clinical Challenges,” Journal Control Release 245 (2017): 95-107.

[99] S. Pawar, M. A. Rauf, H. Abdelhady, and A. K. Iyer, “Tau-Targeting Nanoparticles for Treatment of Alzheimer's Disease,” Exploration (2024): 20230137.

[100] D. A. Butterfield, “Perspectives on Oxidative Stress in Alzheimer's Disease and Predictions of Future Research Emphases,” Journal of Alzheimer's Disease 64 (2018): S469-S479.

[101] S. Haq, J. Grondin, S. Banskota, and W. I. Khan, “Autophagy: Roles in Intestinal Mucosal Homeostasis and Inflammation,” Journal of Biomedical Science 26 (2019): 19.

[102] Y. Kwon, Y. Bang, S. H. Moon, A. Kim, and H. J. Choi, “Amitriptyline Interferes With Autophagy-Mediated Clearance of Protein Aggregates via Inhibiting Autophagosome Maturation in Neuronal Cells,” Cell Death and Disease 11 (2020): 874.

[103] B. R. Cardoso, T. P. Ong, W. Jacob-Filho, O. Jaluul, M. I. Freitas, and S. M. Cozzolino, “Nutritional Status of Selenium in Alzheimer's Disease Patients,” British Journal of Nutrition 103 (2010): 803-806.

[104] Y. T. Tung, W. M. Hsu, B. J. Wang, et al., “Sodium Selenite Inhibits γ-Secretase Activity Through Activation of ERK,” Neuroscience Letters 440 (2008): 38-43.

[105] Z. H. Zhang, C. Chen, Q. Y. Wu, et al., “Selenomethionine Reduces the Deposition of Beta-Amyloid Plaques by Modulating β-Secretase and Enhancing Selenoenzymatic Activity in a Mouse Model of Alzheimer's Disease,” Metallomics 8 (2016): 782-789.

[106] C. P. Yue, Z. F. Shan, Y. B. Tan, et al., “His-Rich Domain of Selenoprotein P Ameliorates Neuropathology and Cognitive Deficits by Regulating TrkB Pathway and Zinc Homeostasis in an Alzheimer Model of Mice,” ACS Chemical Neuroscience 11 (2020): 4098-4110.

[107] J. van Eersel, Y. D. Ke, X. Liu, et al., “Sodium Selenate Mitigates Tau Pathology, Neurodegeneration, and Functional Deficits in Alzheimer's Disease Models,” Proceedings National Academy of Science USA 107 (2010): 13888-13893.

[108] Y. Aman, T. Schmauck-Medina, M. Hansen, et al., “Autophagy in Healthy Aging and Disease,” Nature Aging 1 (2021): 634-650.

[109] Z. Zhang, X. Yang, Y. Q. Song, and J. Tu, “Autophagy in Alzheimer's Disease Pathogenesis: Therapeutic Potential and Future Perspectives,” Ageing Research Reviews 72 (2021): 101464.

[110] T. X. Yu, H. K. Chung, L. Xiao, et al., “Long Noncoding RNA H19 Impairs the Intestinal Barrier by Suppressing Autophagy and Lowering Paneth and Goblet Cell Function,” Cellular and Molecular Gastroenterology and Hepatology 9 (2020): 611-625.

[111] C. Tong, P. Li, L. H. Yu, et al., “Selenium-Rich Yeast Attenuates Ochratoxin A-Induced Small Intestinal Injury in Broiler Chickens by Activating the Nrf2 Pathway and Inhibiting NF-KB Activation,” Journal of Functional Foods 66 (2020): 103784.

[112] Z. H. Zhang, L. Wen, Q. Y. Wu, et al., “Long-Term Dietary Supplementation With Selenium-Enriched Yeast Improves Cognitive Impairment, Reverses Synaptic Deficits, and Mitigates Tau Pathology in a Triple Transgenic Mouse Model of Alzheimer's Disease,” Journal of Agricultural and Food Chemistry 65 (2017): 4970-4979.

[113] J. Zhang, H. C. Zhou, H. Li, Z. W. Ying, and X. Q. Liu, “Research Progress on Separation of Selenoproteins/Se-Enriched Peptides and Their Physiological Activities,” Food and Function 12 (2021): 1390-1401.

[114] M. F. Chen, Q. P. Wu, Z. J. Zhu, et al., “Selenium-Enriched Foods and Their Ingredients: As Intervention for the Vicious Cycle Between Autophagy and Overloaded Stress Responses in Alzheimer's Disease,” Critical Reviews in Food Science and Nutrition 64 (2023): 6672-6685.

[115] G. L. Song, Z. H. Zhang, L. Wen, et al., “Selenomethionine Ameliorates Cognitive Decline, Reduces Tau Hyperphosphorylation, and Reverses Synaptic Deficit in the Triple Transgenic Mouse Model of Alzheimer's Disease,” Journal of Alzheimer's Disease 41 (2014): 85-99.

[116] Z. H. Zhang, Q. Y. Wu, R. Zheng, et al., “Selenomethionine Mitigates Cognitive Decline by Targeting both Tau Hyperphosphorylation and Autophagic Clearance in an Alzheimer's Disease Mouse Model,” Journal of Neuroscience 37 (2017): 2449-2462.

[117] Z. H. Zhang, C. Chen, S. Z. Jia, et al., “Selenium Restores Synaptic Deficits by Modulating NMDA Receptors and Selenoprotein K in an Alzheimer's Disease Model,” Antioxidants and Redox Signaling 35 (2021): 863-884.

[118] J. Wang, Z. Wang, Y. Li, et al., “Blood Brain Barrier-Targeted Delivery of Double Selenium Nanospheres Ameliorates Neural Ferroptosis in Alzheimer's Disease,” Biomaterials 302 (2023): 122359.

[119] G. E. Hardingham and H. Bading, “Synaptic Versus Extrasynaptic NMDA Receptor Signalling: Implications for Neurodegenerative Disorders,” Nature Reviews Neuroscience 11 (2010): 682-696.

[120] Y. Huang, W. Shen, J. Su, et al., “Modulating the Balance of Synaptic and Extrasynaptic NMDA Receptors Shows Positive Effects Against Amyloid-β-Induced Neurotoxicity,” Journal of Alzheimer's Disease 57 (2017): 885-897.

[121] S. Verma, F. W. Hoffmann, M. Kumar, et al., “Selenoprotein K Knockout Mice Exhibit Deficient Calcium Flux in Immune Cells and Impaired Immune Responses,” Journal of Immunology 186 (2011): 2127-2137.

[122] L. Lv, L. Chai, J. Wang, et al., “Selenoprotein K Enhances STING Oligomerization to Facilitate Antiviral Response,” Plos Pathogens 19 (2023): e1011314.

[123] S. Z. Jia, X. W. Xu, Z. H. Zhang, et al., “Selenoprotein K Deficiency-Induced Apoptosis: A Role for Calpain and the ERS Pathway,” Redox Biology 47 (2021): 102154.

[124] Z. H. Zhang and G. L. Song, “Roles of Selenoproteins in Brain Function and the Potential Mechanism of Selenium in Alzheimer's Disease,” Frontiers in Neuroscience 15 (2021): 646518.

[125] W. L. Zhang, H. Q. Chen, L. Y. Ding, et al., "The dissolution, reassembly and further clearance of amyloid-β fibrils by tailor-designed dissociable nanosystem for Alzheimer's disease therapy," Exploration 3 (2023): 20230048.

[126] Q. Feng, X. Zhang, N. Zhang, et al., “The Dissolution, Reassembly and Further Clearance of Amyloid-β Fibrils by Tailor-Designed Dissociable Nanosystem for Alzheimer's Disease Therapy,” Exploration 4 (2024): 20230048.

[127] P. Ouyang, Z. Y. Cai, J. Y. Peng, et al., “SELENOK-Dependent CD36 Palmitoylation Regulates Microglial Functions and Aβ Phagocytosis,” Redox Biology 70 (2024): 103064.

[128] L. G. Jia, W. J. Wang, Y. S. Yan, et al., “General Aggregation-Induced Emission Probes for Amyloid Inhibitors with Dual Inhibition Capacity Against Amyloid β-Protein and α-Synuclein,” ACS Applied Materials and Interfaces 12 (2020): 31182-31194.

[129] M. Conrad and B. Proneth, “Selenium: Tracing Another Essential Element of Ferroptotic Cell Death,” Cell Chemical Biology 27 (2020): 409-419.

[130] Y. B. Miao, K. H. Chen, C. T. Chen, et al., “A Noninvasive Gut-to-Brain Oral Drug Delivery System for Treating Brain Tumors,” Advanced Materials 33 (2021): e2100701.

[131] R. Ward, F. A. Zucca, J. H. Duyn, R. R. Crichton, and L. Zecca, “The Role of Iron in Brain Ageing and Neurodegenerative Disorders,” Lancet Neurology 13 (2014): 1045-1060.

[132] C. Faustino, P. Rijo, and C. P. Reis, “Nanotechnological Strategies for Nerve Growth Factor Delivery: Therapeutic Implications in Alzheimer's Disease,” Pharmacological Research 120 (2017): 68-87.

[133] L. C. Yang, J. Sun, W. J. Xie, Y. A. Liu, and J. Liu, “Dual-Functional Selenium Nanoparticles Bind To and Inhibit Amyloid β Fiber Formation in Alzheimer's Disease,” Journal of Materials Chemistry B 5 (2017): 5954-5967.

[134] Y. Y. Huang, L. Z. He, W. Liu, et al., “Selective Cellular Uptake and Induction of Apoptosis of Cancer-Targeted Selenium Nanoparticles,” Biomaterials 34 (2013): 7106-7116.

[135] X. H. Gao, J. Qian, S. Y. Zheng, et al., “Overcoming the Blood-Brain Barrier for Delivering Drugs into the Brain by Using Adenosine Receptor Nanoagonist,” ACS Nano 8 (2014): 3678-3689.

[136] B. R. Bloem, M. S. Okun, and C. Klein, “Parkinson's Disease,” Lancet 397 (2021): 2284-2303.

[137] X. Dong-Chen, C. Yong, X. Yang, S. Chen-Yu, and P. Li-Hua, “Signaling Pathways in Parkinson's Disease: Molecular Mechanisms and Therapeutic Interventions,” Signal Transduction and Targeted Therapy 8 (2023): 73.

[138] B. G. Trist, D. J. Hare, and K. L. Double, “Oxidative Stress in the Aging Substantia nigra and the Etiology of Parkinson's Disease,” Aging Cell 18 (2019): e13031.

[139] J. H. K. Man, L. Groenink, and M. Caiazzo, “Cell Reprogramming Approaches in Gene- and Cell-Based Therapies for Parkinson's Disease,” Journal of Controlled Release 286 (2018): 114-124.

[140] K. Manoutcharian and G. Gevorkian, “Recombinant Antibody Fragments for Immunotherapy of Parkinson's Disease,” Biodrugs 38 (2024): 249-257.

[141] R. R. Darehbagh, S. A. Seyedoshohadaei, R. Ramezani, and N. Rezaei, “Stem Cell Therapies for Neurological Disorders: Current Progress, Challenges, and Future Perspectives,” European Journal of Medical Research 29 (2024): 386.

[142] S. Paillusson, P. Gomez-Suaga, R. Stoica, et al., “α-Synuclein Binds to the ER-Mitochondria Tethering Protein VAPB to Disrupt Ca²⁺ Homeostasis and Mitochondrial ATP Production,” Acta Neuropathologica 134 (2017): 129-149.

[143] M. Kasten, C. Hartmann, J. Hampf, et al., “Genotype-Phenotype Relations for the Parkinson's Disease Genes Parkin, PINK1, DJ1: MDSGene Systematic Review,” Movement Disorders 33 (2018): 730-741.

[144] S. Tilve, F. Difato, and E. Chieregatti, “Cofilin 1 Activation Prevents the Defects in Axon Elongation and Guidance Induced by Extracellular Alpha-Synuclein,” Scientific Reports 5 (2015): 16524.

[145] I. Choi, Y. Zhang, S. P. Seegobin, et al., “Microglia Clear Neuron-Released α-Synuclein via Selective Autophagy and Prevent Neurodegeneration,” Nature Communications 11 (2020): 1386.

[146] L. Puspita, S. Y. Chung, and J. W. Shim, “Oxidative Stress and Cellular Pathologies in Parkinson's Disease,” Molecular Brain 10 (2017): 53.

[147] P. Pinton, “Mitochondria-Associated Membranes (MAMs) and Pathologies,” Cell Death and Disease 9 (2018): 413.

[148] A. Kouli, L. R. B. Spindler, T. D. Fryer, et al., “Neuroinflammation Is Linked to Dementia Risk in Parkinson's Disease,” Brain 147 (2024): 923-935.

[149] J. Trinh, F. M. J. Zeldenrust, J. Huang, et al., “Genotype-Phenotype Relations for the Parkinson's Disease Genes SNCA, LRRK2, VPS35: MDSGene Systematic Review,” Movement Disorders 33 (2018): 1857-1870.

[150] Y. Zhang, H. Yang, D. Wei, et al., “Mitochondria-Targeted Nanoparticles in Treatment of Neurodegenerative Diseases,” Exploration 1 (2021): 20210115.

[151] S. Giacoppo, M. Galuppo, R. S. Calabrò, et al., “Heavy Metals and Neurodegenerative Diseases: An Observational Study,” Biological Trace Element Research 161 (2014): 151-160.

[152] V. Calabrese, C. Mancuso, A. Ravagna, et al., “In Vivo Induction of Heat Shock Proteins in the Substantia nigra Following L-DOPA Administration is Associated With Increased Activity of Mitochondrial Complex I and Nitrosative Stress in Rats: Regulation by Glutathione Redox State,” Journal of Neurochemistry 101 (2007): 709-717.

[153] X. Zhang, R. P. Liu, W. H. Cheng, and J. H. Zhu, “Prioritized Brain Selenium Retention and Selenoprotein Expression: Nutritional Insights Into Parkinson's Disease,” Mechanisms of Ageing and Development 180 (2019): 89-96.

[154] S. Z. Imam and S. F. Ali, “Selenium, an Antioxidant, Attenuates Methamphetamine-Induced Dopaminergic Toxicity and Peroxynitrite Generation,” Brain Research 855 (2000): 186-191.

[155] J. H. Ellwanger, P. Molz, D. R. Dallemole, et al., “Selenium Reduces Bradykinesia and DNA Damage in a Rat Model of Parkinson's Disease,” Nutrition 31 (2015): 359-365.

[156] H. B. Sun, “Association of Soil Selenium, Strontium, and Magnesium Concentrations with Parkinson's Disease Mortality Rates in the USA,” Environmental Geochemistry and Health 40 (2018): 349-357.

[157] P. Klivenyi, O. A. Andreassen, R. J. Ferrante, et al., “Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine,” Journal of Neuroscience 20 (2000): 1-7.

[158] D. G. Liang, A. M. Minikes, and X. J. Jiang, “Ferroptosis at the Intersection of Lipid Metabolism and Cellular Signaling,” Molecular Cell 82 (2022): 2215-2227.

[159] J. Sun, X. M. Lin, D. H. Lu, et al., “Midbrain Dopamine Oxidation Links Ubiquitination of Glutathione Peroxidase 4 to Ferroptosis of Dopaminergic Neurons,” Journal of Clinical Investigation 133 (2023): e165228.

[160] K. Xu, P. Huang, Y. Wu, et al., “Engineered Selenium/Human Serum Albumin Nanoparticles for Efficient Targeted Treatment of Parkinson's Disease via Oral Gavage,” ACS Nano 17 (2023): 19961-19980.

[161] C. Sun, Z. Du, X. Liu, et al., “Selenium Forms and Dosages Determined Their Biological Actions in Mouse Models of Parkinson's Disease,” Nutrients 15 (2022): 11.

[162] M. P. van der Brug, J. Blackinton, J. Chandran, et al., “RNA Binding Activity of the Recessive Parkinsonism Protein DJ-1 Supports Involvement in Multiple Cellular Pathways,” Proceedings National Academy of Science USA 105 (2008): 10244-10249.

[163] D. N. Hauser, A. A. Dukes, A. D. Mortimer, and T. G. Hastings, “Dopamine Quinone Modifies and Decreases the Abundance of the Mitochondrial Selenoprotein Glutathione Peroxidase 4,” Free Radical Biology and Medicine 65 (2013): 419-427.

[164] J. Aaseth, J. Alexander, G. Bjorklund, et al., “Treatment Strategies in Alzheimer's Disease: A Review With Focus on Selenium Supplementation,” Biometals 29 (2016): 827-839.

[165] R. G. Wells, L. E. Neilson, A. W. McHill, and A. L. Hiller, “Dietary Fasting and Time-Restricted Eating in Huntington's Disease: Therapeutic Potential and Underlying Mechanisms,” Translational Neurodegeneration 13 (2024): 17.

[166] J. M. van der Burg, M. Bjorkqvist, and P. Brundin, “Beyond the Brain: Widespread Pathology in Huntington's Disease,” Lancet Neurology 8 (2009): 765-774.

[167] G. P. Bates, R. Dorsey, J. F. Gusella, et al., “Huntington Disease,” Nature Reviews Disease Primers 1 (2015): 15005.

[168] W. S. Cong, R. Bai, Y. F. Li, L. M. Wang, and C. Y. Chen, “Selenium Nanoparticles as an Efficient Nanomedicine for the Therapy of Huntington's Disease,” ACS Applied Materials and Interfaces 11 (2019): 34725-34735.

[169] J. W. Shin, E. P. Hong, D. E. Choi, et al., “Allele-Specific Silencing of the Gain-Of-function Mutation in Huntington's Disease Using CRISPR/Cas9,” JCI Insight 7 (2022): e141042.

[170] M. A. Sorolla, G. Reverter-Branchat, J. Tamarit, I. Ferrer, J. Ros, and E. Cabiscol, “Proteomic and Oxidative Stress Analysis in Human Brain Samples of Huntington Disease,” Free Radical Biology and Medicine 45 (2008): 667-678.

[171] J. Zhou, W. Zhang, Z. Cao, et al., “Association of Selenium Levels With Neurodegenerative Disease: A Systemic Review and Meta-Analysis,” Nutrients 24 (2023): 3706.

[172] Z. Lu, E. Marks, J. Chen, et al., “Altered Selenium Status in Huntington's Disease: Neuroprotection by Selenite in the N171-82Q Mouse Model,” Neurobiology of Disease 71 (2014): 34-42.

[173] M. Ribeiro, T. R. Rosenstock, T. Cunha-Oliveira, I. L. Ferreira, C. R. Oliveira, and A. C. Rego, “Glutathione Redox Cycle Dysregulation in Huntington's Disease Knock-In Striatal Cells,” Free Radical Biology and Medicine 53 (2012): 1857-1867.

[174] R. Shema, R. Kulicke, G. S. Cowley, R. Stein, D. E. Root, and M. Heiman, “Synthetic Lethal Screening in the Mammalian Central Nervous System Identifies Gpx6 as a Modulator of Huntington's Disease,” Proceedings National Academy of Science USA 112 (2015): 268-272.

[175] P. K. Mandal, A. Seiler, T. Perisic, et al., “System X(c)− and Thioredoxin Reductase 1 Cooperatively Rescue Glutathione Deficiency,” Journal of Biological Chemistry 285 (2010): 22244-22253.

[176] B. Speckmann and T. Grune, “Epigenetic Effects of Selenium and Their Implications for Health,” Epigenetics 10 (2015): 179-190.

[177] H. Steinbrenner, B. Speckmann, and H. Sies, “Toward Understanding Success and Failures in the Use of Selenium for Cancer Prevention,” Antioxidants and Redox Signaling 19 (2013): 181-191.

[178] S. J. Fairweather-Tait, Y. Bao, M. R. Broadley, et al., “Selenium in Human Health and Disease,” Antioxidants and Redox Signaling 14 (2011): 1337-1383.

[179] O. Leiter, Z. Zhuo, R. Rust, et al., “Selenium Mediates Exercise-induced Adult Neurogenesis and Reverses Learning Deficits Induced by Hippocampal Injury and Aging,” Cell Metabolism 34 (2022): 408-423.

[180] J. Fu, Q. Wang, N. Wang, et al., “Serum and Urinary Essential Trace Elements in Association With Major Depressive Disorders: A Case-Control Study,” Front Psychiatry 14 (2023): 1297411.

[181] A. V. Skalny, N. V. Simashkova, T. P. Klyushnik, et al., “Assessment of Serum Trace Elements and Electrolytes in Children with Childhood and Atypical Autism,” Journal of Trace Elements in Medicine and Biology 43 (2017): 9-14.

[182] A. A. Tinkov, M. G. Skalnaya, N. V. Simashkova, et al., “Association Between Catatonia and Levels of Hair and Serum Trace Elements and Minerals in Autism Spectrum Disorder,” Biomedicine and Pharmacotherapy 109 (2019): 174-180.

[183] R. A. Heller, J. Seelig, T. Bock, et al., “Relation of Selenium Status to Neuro-Regeneration After Traumatic Spinal Cord Injury,” Journal of Trace Elements in Medicine and Biology 51 (2019): 141-149.

[184] N. Senol, M. Naziroglu, and V. Yuruker, “N-Acetylcysteine and Selenium Modulate Oxidative Stress, Antioxidant Vitamin and Cytokine Values in Traumatic Brain Injury-Induced Rats,” Neurochemical Research 39 (2014): 685-692.

[185] H. Hu, H. Gao, K. Wang, et al., “Effective Treatment of Traumatic Brain Injury by Injection of a Selenium-Containing Ointment,” Acta Biomaterialia 187 (2024): 161-171.

[186] A. Anjum, M. D. Yazid, M. Fauzi Daud, et al., “Spinal Cord Injury: Pathophysiology, Multimolecular Interactions, and Underlying Recovery Mechanisms,” International Journal of Molecular Sciences 21 (2020): 7533.

[187] Z. Ji, J. Zheng, Y. Ma, et al., “Emergency Treatment and Photoacoustic Assessment of Spinal Cord Injury Using Reversible Dual-Signal Transform-Based Selenium Antioxidant,” Small 19 (2023): e2207888.

[188] S. Rao, Y. Lin, R. Lin, et al., “Traditional Chinese Medicine Active Ingredients-Based Selenium Nanoparticles Regulate Antioxidant Selenoproteins for Spinal Cord Injury Treatment,” Journal Nanobiotechnology 20 (2022): 278.

RIGHTS & PERMISSIONS

2025 The Author(s). Exploration published by Henan University and John Wiley & Sons Australia, Ltd.